Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Drug

NMPA Approves XZenith Biopharm’s Anaprazole for Duodenal Ulcer Treatment

Fineline Cube Jun 26, 2023

The National Medical Product Administration (NMPA) has granted marketing approval for anaprazole, a proton pump...

Company Drug

Sichuan Kelun’s SKB264 Earns Breakthrough Therapy Designation for Breast Cancer Treatment

Fineline Cube Jun 26, 2023

The Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Kelun Pharmaceutical Co.,...

Company Drug

Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023

Fineline Cube Jun 26, 2023

China’s Brii Biosciences (HKG: 2137) announced that its strategic partners, Vir Biotechnology Inc., (NASDAQ: VIR)...

Company Deals

Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs

Fineline Cube Jun 26, 2023

Japan’s Shionogi & Co., Ltd (TYO: 4507) announced on June 26, 2023, its planned acquisition...

Company Deals Drug

Innovent Biologics and RemeGen Partner on Clinical Study for PD-1 Inhibitor and ADC Drugs

Fineline Cube Jun 26, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has entered into a clinical study and supply cooperation...

Company Drug

Sino-Cuban JV Biotech Pharmaceutical Receives NMPA Approval for Nimotuzumab in Pancreatic Cancer

Fineline Cube Jun 25, 2023

Sino-Cuban joint venture (JV) Biotech Pharmaceutical Limited (BPL) announced last week that it has received...

Company Drug

Sarepta Therapeutics’ Elevidys Receives FDA Accelerated Approval for Duchenne Muscular Dystrophy

Fineline Cube Jun 25, 2023

US-based Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has announced that the U.S. Food and Drug Administration...

Company Drug

S-Evans Biosciences Receives NMPA Tacit Approval for Stem Cell Therapy in ARDS

Fineline Cube Jun 25, 2023

S-Evans Biosciences, a stem cell specialist based in Hangzhou, has obtained tacit clinical trial approval...

Company Deals

Kite Pharma’s Yescarta Marketing Rights Transferred to Gilead Sciences K.K. in Japan

Fineline Cube Jun 25, 2023

US immunotherapy specialist Kite Pharma, Inc. has announced that the Marketing Authorization for Yescarta (axicabtagene...

Company Drug

Hopstem Biotechnology’s hNPC01 Receives Tacit Approval for Stroke Sequelae Treatment from CDE

Fineline Cube Jun 25, 2023

Hopstem Biotechnology Co., Ltd, a neural stem cell specialist founded by neuroscientists and stem-cell biologists...

Company Deals

Edding Pharma Aims for Fifth IPO Attempt on Hong Kong Stock Exchange

Fineline Cube Jun 25, 2023

China-based Edding Pharma is gearing up for its fifth attempt to hold an initial public...

Drug Policy / Regulatory

CDE Releases Guidelines for Clinical Trials of Stem Cell Therapies and Derived Products

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a set of “Guidelines for Clinical Trial...

Company Drug

Sciwind Biosciences Leads China’s Anti-Obesity Drug Market with GLP-1 Analog Ecnoglutide

Fineline Cube Jun 25, 2023

Sino-US biotech Sciwind Biosciences Co., Ltd has positioned itself as a frontrunner in China’s race...

Drug Policy / Regulatory

CDE Releases Draft Guidelines for Antibody Drug Conjugate Research and Evaluation

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a draft set of “Guiding Principles for...

Company Deals

Aureka Biotechnologies Secures $10 Million in Seed Funding for AI-Driven Biotechnology

Fineline Cube Jun 25, 2023

Aureka Biotechnologies Inc., a California-based artificial intelligence (AI)-empowered biotech company, has successfully raised USD 10...

Company Drug

Jiangsu Hengrui’s Camrelizumab Earns Full Approval for Advanced Hepatocellular Carcinoma in China

Fineline Cube Jun 21, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the transition of its programmed death-1 (PD-1)...

Company Drug

Biocytogen Pharmaceuticals Receives CNIPA Patent for RenMab Human Antibody Mice Platform

Fineline Cube Jun 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced receiving a prestigious patent award...

Company Drug

BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447

Fineline Cube Jun 21, 2023

China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in...

Company Drug

Jiangsu Hengrui Pharmaceutials’ SHR-1209 for Hypercholesterolemia Accepted for NMPA Review

Fineline Cube Jun 21, 2023

China-based Jiangsu Hengrui Pharmaceutials (SHA: 600276) has announced that a market filing for its Category...

Company Drug

Minghui Pharmaceutical Achieves First Dosing Milestone in Phase I Studies for ADC Candidates

Fineline Cube Jun 21, 2023

China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in...

Posts pagination

1 … 453 454 455 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.